CONSIDERATIONS TO KNOW ABOUT TRASTUZUMAB HOW DOES IT WORK

One of the most below-investigated “driving forces” involved with trastuzumab resistance is PTEN. Nagata et al. (2004) described the lack of PTEN was observed in 36% of HER2-beneficial Key breast tumor specimens from individuals with stage IV disease. Furthermore, they also confirmed that individuals with PTEN-deficient tumors had remarkably de